Browse > Article
http://dx.doi.org/10.4014/jmb.1503.03033

Anticancer and Anti-Inflammatory Activity of Probiotic Lactococcus lactis NK34  

Han, Kyoung Jun (Department of Food Science and Biotechnology of Animal Resources, Konkuk University)
Lee, Na-Kyoung (Department of Food Science and Biotechnology of Animal Resources, Konkuk University)
Park, Hoon (Department of Food Science, Sun Moon University)
Paik, Hyun-Dong (Department of Food Science and Biotechnology of Animal Resources, Konkuk University)
Publication Information
Journal of Microbiology and Biotechnology / v.25, no.10, 2015 , pp. 1697-1701 More about this Journal
Abstract
The anticancer and anti-inflammatory activities of probiotic Lactococcus lactis NK34 were demonstrated. Treatment of cancer cells such as SK-MES-1, DLD-1, HT-29, LoVo, AGS, and MCF-7 cells with 106 CFU/well of L. lactis NK34 resulted in strong inhibition of proliferation (>77% cytotoxicity, p < 0.05). The anti-inflammatory activity of L. lactis NK34 was also demonstrated in lipopolysaccharide-induced RAW 264.7 cells, where the production of nitric oxide and proinflammatory cytokines (tumor necrosis factor-α, interleukin-18, and cyclooxygenase-2) was reduced. These results suggest that L. lactis NK34 could be used as a probiotic microorganism to inhibit the proliferation of cancer cells and production of proinflammatory cytokines.
Keywords
Probiotic; Lactococcus lactis; anticancer activity; anti-inflammatory activity; cytokine;
Citations & Related Records
연도 인용수 순위
  • Reference
1 Chang JH, Shin YY, Chae SK, Chee KM. 2010. Probiotic characteristics of lactic acid isolated from kimchi. J. Appl. Microbiol. 109: 220-230.   DOI
2 Lee NK, Noh JE, Choi GH, Park E, Chang HI, Yun CW, et al. 2007. Potential probiotic properties of Lactococcus lactis NK34 isolated from jeotgal. Food Sci. Biotechnol. 16: 843-847.
3 Lee NK, Kim SY, Han KJ, Eom SJ, Paik HD. 2014. Probiotic potential of Lactobacillus strains with anti-allergic effects from kimchi for yogurt starters. LWT Food Sci. Technol. 58: 130-134.   DOI
4 Zhou X, Wang Y, Li W. 2010. Inhibition ability of probiotic, Lactococcus lactis, against A. hydrophila and study of its immunostimulatory effect in tilapia (Oreochromis niloticus). Int. J. Eng. Sci. Technol. 2: 73-80.
5 Baumgart DC, Thomas S, Przesdzing I, Metzke D, Bielecki C, Lehmann SM, et al. 2009. Exaggerated inflammatory response of primary human myeloid dendritic cells to lipopolysaccharide in patients with inflammatory bowel disease. Clin. Exp. Immunol. 157: 423-436.   DOI
6 Commane D, Hughes R, Shortt C, Rowland I. 2005. The potential mechanisms involved in the anti-carcinogenic action of probiotics. Mut. Res. 591: 276-289.   DOI
7 Festen EAM, Szperl AM, Weersma RK, Wikmenga C, Wapenaar MC. 2009. Inflammatory bowel disease and celiac disease: overlaps in the pathology and genetics, and their potential drug targets. Curr. Drug Targets Immune Endocr. Metab. Disord. 9: 199-218.   DOI
8 Heo WS, Kim YR, Kim EY, Bai S, Kong IS. 2013. Effects of dietary probiotic, Lactococcus lactis subsp. lactis I2, supplementation on the growth and immune response of olive flounder (Paralichthys olivaceus). Aquaculture 376-379: 20-24.   DOI
9 Lakatos L, Lakatos PL. 2006. Is the incidence and prevalence of inflammatory bowel diseases increasing in Eastern Europe? Postgrad. Med. J. 82: 332-337.   DOI
10 Otte JM, Mahjurian-Namari R, Brand S, Werner I, Schmidt WE, Schmitz F. 2009. Probiotics regulate the expression of COX-2 in intestinal epithelial cells. Nutr. Cancer 61: 103-113.   DOI
11 Ouwehand AC. 2011. Allergenic effects of probiotics. J. Nutr. 137: 794S-797S.
12 Lee NK, Son SH, Jeon EB, Kim GH, Lee JY, Paik HD. 2015. The prophylactic effect of probiotic Bacillus polyfermenticus KU3 against cancer cells. J. Funct. Foods 14: 513-518.   DOI
13 Marcinkiewicz J, Ciszek M, Bobek M, Strus M, Heczko PB, Kurnyta M, et al. 2007. Differential inflammatory mediator response in vitro from murine macrophages to lactobacilli and pathogenic intestinal bacteria. Int. J. Exp. Pathol. 88: 155-164.   DOI
14 O’Sullivan GC, Kelly P, O’Halloran S, Collins C, Collins JK, Dunne C, Shanahan F. 2005. Probiotics: an emerging therapy. Curr. Pharm. Des. 11: 3-10.   DOI
15 Shukla R, Iliev I, Goyal A. 2014. Leuconostoc mesenteroides NRRL B-1149 as probiotic and its dextran with anticancer properties. J. Biosci. Biotechnol. 3: 79-87.
16 Westbrook AM, Szakmary A, Schiestl RH. 2010. Mechanisms of intestinal inflammation and development of associated cancers: lessons learned from mouse models. Mutat. Res. 705: 40-59.   DOI